Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - hydrochlorothiazide; dexamethasone - solution for injection - 50, 0.5 milligram(s)/millilitre - hydrochlorothiazide, combinations - cattle, non food-producing horses - cardiovascular

Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - dexamethasone; hydrochlorothiazide - oral powder - 0.25, 75.0 milligram(s)/gram - hydrochlorothiazide, combinations - cattle, non food-producing horses - cardiovascular

Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - hydrochlorothiazide, dexamethasone - solution for injection - unknown - hydrochlorothiazide, combinations - bovine, equine non food - cardiovascular

Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - dexamethasone, hydrochlorothiazide - oral powder - 0.025/7.5 - hydrochlorothiazide, combinations - bovine, equine non food - cardiovascular

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate 10 mg in 10 ml - milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are contraindicated in patients who are hypersensitive to it.

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone 1 mg in 1 ml - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection is contraindicated in patients who are hypersensitive to it.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone 200 ug in 1 ml - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection is contraindicated in patients who are hypersensitive to it.

United States - English - NLM (National Library of Medicine)

hospira, inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone 200 ug in 1 ml - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate is contraindicated in patients who are hypersensitive to it. to open tear outer wrap at notch and remove solution container. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. preparation for administration (use aseptic technique) - close flow control clamp of ad

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - milrinone, quantity: 10 mg - injection, concentrated - excipient ingredients: glucose; water for injections; sodium hydroxide; lactic acid - milrinone-baxter is indicated for the short term (48 hours) intravenous therapy of severe congestive heart failure patients in intensive care and coronary care units not responding to other therapy (e.g. digoxin, diuretics, vasodilators, including ace inhibitors). the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. ,milrinone-baxter is also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone 0.2 mg in 1 ml - milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone is contraindicated in patients who are hypersensitive to it. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.